Insider Buying: VBI Vaccines (VBIV) Insider Purchases $30,500.00 in Stock

VBI Vaccines (NASDAQ:VBIV) insider Francisco Diaz-Mitoma bought 10,000 shares of the stock in a transaction that occurred on Friday, May 11th. The shares were purchased at an average price of $3.05 per share, for a total transaction of $30,500.00. Following the purchase, the insider now owns 268,839 shares in the company, valued at approximately $819,958.95. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

VBIV stock remained flat at $$3.44 during mid-day trading on Thursday. 3,110 shares of the company’s stock traded hands, compared to its average volume of 143,124. VBI Vaccines has a 1-year low of $3.20 and a 1-year high of $3.33. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.72 and a current ratio of 3.77.

VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). The company had revenue of $0.18 million during the quarter, compared to analysts’ expectations of $0.21 million. VBI Vaccines had a negative return on equity of 47.54% and a negative net margin of 4,607.13%. equities analysts expect that VBI Vaccines will post -0.7 earnings per share for the current fiscal year.

A number of research analysts recently weighed in on VBIV shares. BidaskClub cut shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Saturday, January 20th. Noble Financial restated a “buy” rating on shares of VBI Vaccines in a research note on Friday, March 23rd. Zacks Investment Research cut shares of VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Friday, March 2nd. BMO Capital Markets lifted their target price on shares of VBI Vaccines from $11.00 to $13.00 and gave the company an “outperform” rating in a research note on Thursday, May 10th. Finally, ValuEngine upgraded shares of VBI Vaccines from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. VBI Vaccines currently has a consensus rating of “Hold” and a consensus target price of $9.42.

A number of hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its stake in VBI Vaccines by 7.3% in the 1st quarter. Russell Investments Group Ltd. now owns 491,449 shares of the biopharmaceutical company’s stock worth $1,720,000 after purchasing an additional 33,588 shares in the last quarter. Meitav Dash Investments Ltd. purchased a new stake in VBI Vaccines in the 4th quarter worth $4,664,000. Millennium Management LLC lifted its stake in VBI Vaccines by 92.8% in the 4th quarter. Millennium Management LLC now owns 245,603 shares of the biopharmaceutical company’s stock worth $1,049,000 after purchasing an additional 118,208 shares in the last quarter. TIAA CREF Investment Management LLC lifted its stake in VBI Vaccines by 24.8% in the 4th quarter. TIAA CREF Investment Management LLC now owns 78,369 shares of the biopharmaceutical company’s stock worth $335,000 after purchasing an additional 15,557 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in VBI Vaccines by 52.5% in the 4th quarter. California State Teachers Retirement System now owns 54,460 shares of the biopharmaceutical company’s stock worth $233,000 after purchasing an additional 18,760 shares in the last quarter. Institutional investors and hedge funds own 48.51% of the company’s stock.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus.

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply